CoChat

Latin‐American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients

Halpern, A., Mancini, M. C., Suplicy, H., Zanella, M. T., Repetto, G., Gross, J., Jadzinsky, M., Barranco, J., Aschner, P., Ramirez, L., Matos, A. G. · 2003 · Diabetes, Obesity and Metabolism
Cited by 71

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Aim: To determine if obese non‐insulin‐dependent diabetic patients lose more weight when treated for 24 weeks (6 months) with orlistat (120 mg t.i.d.), in conjunction with a hypocaloric diet plus behavioural counselling, than when treated by placebo (t.i.d.) plus similar instructions. The secondary objectives were to evaluate the effects on glucose profile and to determine the tolerability and safety of orlistat. Design: Double‐blind, parallel, randomized, placebo‐controlled, multicentre study. Subjects: Obese, non‐insulin‐dependent diabetic patients, aged 18–70 years old, with BMI > 27 kg/m 2 , evaluated at 10 Latin‐American centres, in five countries. Efficacy and Tolerability Measurements: After screened, eligible patients passed by a 2‐week placebo run‐in period receiving a hypocaloric diet. On day 0, patients were randomized to orlistat or placebo for 24 weeks. At each visit, body weight, blood pressure and waist circumference were measured. At the screening visit, baseline visit (week 0), and at weeks 8, 16 and 24, a central laboratory was in charge of measuring fasting glucose and insulin, HbA 1c , postprandial glucose and insulin, fasting total cholesterol, HDL‐cholesterol, LDL‐cholesterol, triglycerides, and postprandial triglycerides. Other safety laboratory assessments were measured locally at the screening visit, baseline visit and at the end of the study. Adverse events were assessed at each visit from baseline. Results: After 24 weeks of treatment, the orlistat group lost an average of 4.7% of initial body weight vs. 3.0% in the placebo group (p = 0.0003). A greater weight loss was achieved in the orlistat compared with the placebo group (4.24 ± 0.23 vs. 2.58 ± 1.46 kg, p = 0.0003). Almost twice as many patients receiving orlistat (30% vs. 17%) lost ≥ 5% of initial body weight (p = 0.003). Orlistat treatment plus diet compared to placebo plus diet was associated with significant improvement in glycaemic control, as reflected in decreases in HbA1c (p = 0.04), fasting plasma glucose (p = 0.036) and postprandial glucose (p = 0.05). Orlistat‐treated patients had a mean decrease in glucose levels of 1.00 ± 0.34 mmol/l [3.7%] vs. 0.01 ± 0.30 mmol/l for placebo group, at week 24 and an absolute decrease of HbA1c of 0.61 ± 0.15 vs. a decrease of 0.22 ± 0.14% in the placebo group. Orlistat therapy also resulted in significantly greater improvements than placebo in lipid profile, with reductions in total cholesterol (p = 0.0001) and LDL‐cholesterol (p = 0.002). Mild to moderate transient gastrointestinal events were reported, mainly with orlistat treatment, but their association with withdrawal from the study was low. Conclusion: Orlistat is a useful and an effective therapy in obese diabetic patients, promoting clinically significant weight loss and improved glycaemic control and lipid profile.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1463-1326.2003.00262.x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 71

Metadata

Authors
Halpern, A., Mancini, M. C., Suplicy, H., Zanella, M. T., Repetto, G., Gross, J., Jadzinsky, M., Barranco, J., Aschner, P., Ramirez, L., & Matos, A. G.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2003-04-04
Volume
5
Issue
3
Pages
180-188
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2015747658
Cited by
71
References
6
FWCI
4.99
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Latin‐American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. https://app.cochat.ai/papers/10.1046/j.1463-1326.2003.00262.x
The paper
Halpern, A., Mancini, M. C., Suplicy, H., Zanella, M. T., Repetto, G., Gross, J., Jadzinsky, M., Barranco, J., Aschner, P., Ramirez, L., & Matos, A. G. (2003). Latin‐American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes, Obesity and Metabolism. https://doi.org/10.1046/j.1463-1326.2003.00262.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.